Results 171 to 180 of about 185,507 (355)

Real‐World Treatment Patterns in AERD: An Analysis of ATAD, Biologics, and Combination Therapy

open access: yesInternational Forum of Allergy &Rhinology, Volume 16, Issue 1, Page 99-101, January 2026.
Key Points Contemporary aspirin exacerbated respiratory disorder (AERD) therapy commonly includes aspirin desensitization (55%) and biologics (48%). Aspirin desensitization therapy has higher discontinuation rates than biologics. Patients receiving biologics are younger, and ∼25% of the patients switch to other agents.
Nitish Kumar   +5 more
wiley   +1 more source

Plastic bronchitis in children: 2 cases

open access: diamond, 2009
Yeo Hyang Kim   +3 more
openalex   +1 more source

Racial, ethnic and sex‐specific mechanisms of obstructive sleep apnea and Alzheimer's disease risk

open access: yesAlzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract BACKGROUND Obstructive sleep apnea (OSA) is associated with Alzheimer's disease (AD) risk. Racial‐, ethnic‐, and sex‐specific mechanisms of OSA and AD risk were examined. METHODS We analyzed data from 3978 polysomnography patients without cognitive decline aged ≥ 60 including 663 OSA+ patients (284 non‐Hispanic White, 207 Black, 172 Hispanic ...
Komal Patel Murali   +19 more
wiley   +1 more source

Joint Association of Arterial Stiffness and Depression With New‐Onset Self‐Reported Chronic Obstructive Pulmonary Disease Among Elderly Chinese Population

open access: yesBrain and Behavior, Volume 16, Issue 1, January 2026.
Arterial stiffness and depressive symptoms independently and jointly increased the risk of new‐onset Chronic Obstructive Pulmonary Disease (COPD) in older Chinese adults. Their small bidirectional mediation effects suggest interconnected vascular and psychological pathways contributing to COPD development.
Qinqin Shen   +5 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a BTLA Agonist Antibody (Venanprubart) in Healthy Participants, Patients with Systemic Lupus Erythematosus, and Patients with Psoriasis: Results From Three Phase 1 Studies

open access: yesClinical Pharmacology in Drug Development, Volume 15, Issue 1, January 2026.
Abstract Venanprubart (LY3361237), an agonist antibody to B and T lymphocyte attenuator (BTLA), was developed as a potential treatment for autoimmune disorders, including systemic lupus erythematosus (SLE) and psoriasis. We tested venanprubart in three human Phase 1 safety studies: a single ascending dose (SAD) study in healthy participants (1/2/5/15 ...
Andrew C. Vendel   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy